In a recent trial designed for patients newly diagnosed with AML ineligible for standard induction chemotherapy, azacitidine plus venetoclax was superior to azacitidine alone, also in the subset of IDH1/IDH2- and TP53-mutated patients [146]. This evidence concerns the gene IDH2 and acute myeloid leukemia.